Foghorn Therapeutics price to book ratio FHTX

Market value divided by the book value of the company's net assets, since 2021.

Today, Oct 23, 2026: n/m; not a meaningful number
Last meaningful: 10.0×; Mar 2023
Peer median: 1.6×

Foghorn Therapeutics' price to book ratio is not a meaningful number today: shareholders' equity was zero, negative or not reported, so price to book does not exist.

It was last meaningful in Mar 2023, at 10.0×.

Price to book ratio over time

Open the interactive chart, with overlays and comparisons

Year by year

Year	End of year	Low	High
2023	10.0×	9.7×	15.0×
2022	11.0×	4.1×	15.7×
2021	10.5×	2.5×	10.5×

Against its peers

Companies in Drug Manufacturers - General nearest Foghorn Therapeutics' size, closest first, today.

Company	Price to book ratio
FHTXFoghorn Therapeutics	n/m
LFVNLifevantage	2.2×
NATRNatures Sunshine Products	1.3×
SPROSpero Therapeutics	1.5×
ATNMActinium Pharmaceuticals	1.6×
ARVNArvinas	0.8×
PBYIPuma Biotechnology	4.1×
IRWDIronwood Pharmaceuticals	n/m
ZVRAZevra Therapeutics	2.7×
CRMDCorMedix	1.3×
COLLCollegium Pharmaceutical	2.4×
Peer median	1.6×

What the price to book ratio tells you

Market value divided by the accounting value of the company's net assets. Below 1 means the market values the business at less than what it owns on paper.

Book value misses brands, software and people, so asset-light companies always look expensive on it. Most useful for banks and industrials.

More on Foghorn Therapeutics

Valuation data, not investment advice. Prices as of Oct 23, 2026. Reported figures come from the company's filings with the SEC.